MXPA05012101A - Bolsillo de union al inhibidor de polimerasa ns5b del virus de la hepatitis c. - Google Patents
Bolsillo de union al inhibidor de polimerasa ns5b del virus de la hepatitis c.Info
- Publication number
- MXPA05012101A MXPA05012101A MXPA05012101A MXPA05012101A MXPA05012101A MX PA05012101 A MXPA05012101 A MX PA05012101A MX PA05012101 A MXPA05012101 A MX PA05012101A MX PA05012101 A MXPA05012101 A MX PA05012101A MX PA05012101 A MXPA05012101 A MX PA05012101A
- Authority
- MX
- Mexico
- Prior art keywords
- binding pocket
- hepatitis
- ns5b polymerase
- polymerase inhibitor
- hcv ns5b
- Prior art date
Links
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 title abstract 4
- 229940123066 Polymerase inhibitor Drugs 0.000 title 1
- 125000000539 amino acid group Chemical group 0.000 abstract 2
- 150000005829 chemical entities Chemical class 0.000 abstract 1
- 238000012790 confirmation Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La polimerasa NS5B del HCV, cuando se compleja con ciertos inhibidores, adopta una conformacion en la que la region del bucle de dedo definida por los residuos aminoacidos 18 a 35 esta desplazada para exponer un bolsillo de union generalmente definido por los residuos de aminoacidos 392, 393, 395, 396, 399, 424, 425, 428, 429, 492, 493, 494, 495, 496, 500 y 503. Este bolsillo de union recientemente expuesto define una nueva diana en la busqueda de entidades quimicas adicionales que son capaces de unirse a NS5B del HCV y de modular, o preferiblemente inhibir, la actividad de polimerasa NS5B del HCV.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46960403P | 2003-05-09 | 2003-05-09 | |
PCT/CA2004/000676 WO2004099241A1 (en) | 2003-05-09 | 2004-05-05 | Hepatitis c virus ns5b polymerase inhibitor binding pocket |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05012101A true MXPA05012101A (es) | 2006-02-08 |
Family
ID=33435247
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05012101A MXPA05012101A (es) | 2003-05-09 | 2004-05-05 | Bolsillo de union al inhibidor de polimerasa ns5b del virus de la hepatitis c. |
Country Status (12)
Country | Link |
---|---|
US (1) | US7386398B2 (es) |
EP (1) | EP1625154B1 (es) |
JP (1) | JP4584909B2 (es) |
KR (1) | KR101164070B1 (es) |
CN (1) | CN100457776C (es) |
AU (1) | AU2004235848B2 (es) |
CA (1) | CA2522574C (es) |
DK (1) | DK1625154T3 (es) |
ES (1) | ES2456702T3 (es) |
IL (1) | IL171800A (es) |
MX (1) | MXPA05012101A (es) |
WO (1) | WO2004099241A1 (es) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2355687C2 (ru) | 2003-08-01 | 2009-05-20 | Дженелэбс Текнолоджиз, Инк | Бициклические производные имидазола в качестве средства против вирусов семейства flaviviridae |
US7153848B2 (en) | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
US7816348B2 (en) | 2006-02-03 | 2010-10-19 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US8512352B2 (en) * | 2007-04-17 | 2013-08-20 | Lazarus Effect, Inc. | Complex wire formed devices |
CA2693495A1 (en) * | 2007-08-03 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
CA2693997C (en) | 2007-08-03 | 2013-01-15 | Pierre L. Beaulieu | Viral polymerase inhibitors |
WO2009033183A2 (en) * | 2007-09-08 | 2009-03-12 | University Of Florida Research Foundation | Compounds and methods for treatment of hcv and conditions associated with cd81 binding |
BRPI0703586B1 (pt) * | 2007-10-19 | 2018-02-06 | Braskem S.A | Catalisador metaloceno suportado, e, copolímeros de etileno com alfa-olefinas de alto e ultra alto peso molecular |
CN101903351B (zh) | 2007-12-19 | 2014-09-10 | 贝林格尔.英格海姆国际有限公司 | 病毒聚合酶抑制剂 |
KR20110098779A (ko) * | 2008-12-03 | 2011-09-01 | 프레시디오 파마슈티칼스, 인코포레이티드 | Hcv ns5a의 억제제 |
TW201039826A (en) * | 2009-01-12 | 2010-11-16 | Glaxosmithkline Llc | Anti-viral compounds, compositions, and methods of use |
EP2398474A4 (en) * | 2009-02-23 | 2012-12-05 | Presidio Pharmaceuticals Inc | HCV NS5A SHEMMER |
US8993604B2 (en) | 2009-06-30 | 2015-03-31 | Siga Technologies, Inc. | Treatment and prevention of dengue virus infections |
EP2448410A4 (en) * | 2009-06-30 | 2013-12-18 | Siga Technologies Inc | TREATMENT AND PREVENTION OF INFECTIONS WITH THE DENGUE VIRUS |
US20110053892A1 (en) * | 2009-08-31 | 2011-03-03 | Martin Leivers | Imidazo[4,5-d]Pyridazine Compounds For Treating Viral Infections |
US20110065782A1 (en) * | 2009-09-15 | 2011-03-17 | Malliavin Therese | Methods of identifying compounds that inhibit the activation of a biomolecule and methods of treatment using the compounds |
WO2011103063A1 (en) * | 2010-02-19 | 2011-08-25 | Glaxo Group Limited | Therapeutic compounds |
EP2575475A4 (en) * | 2010-05-28 | 2013-11-27 | Presidio Pharmaceuticals Inc | HCV NS5A INHIBITORS |
US8822520B2 (en) | 2010-09-22 | 2014-09-02 | Presidio Pharmaceuticals, Inc. | Substituted bicyclic HCV inhibitors |
US8999967B2 (en) | 2010-09-29 | 2015-04-07 | Presidio Pharmaceuticals, Inc. | Tricyclic fused ring inhibitors of hepatitis C |
BR112013009789A2 (pt) | 2010-10-26 | 2016-07-19 | Presidio Pharmaceuticals Inc | inibidores do vírus da hepatite c |
JP6026425B2 (ja) * | 2010-11-02 | 2016-11-16 | プロビオドルグ エージー | イソグルタミニルシクラーゼの結晶構造 |
KR20190012271A (ko) | 2010-11-17 | 2019-02-08 | 길리애드 파마셋 엘엘씨 | 항바이러스 화합물 |
EP2651927A4 (en) * | 2010-12-15 | 2014-06-04 | Abbvie Inc | ANTIVIRAL CONNECTIONS |
MX2014001721A (es) * | 2011-08-12 | 2017-01-11 | Southern Res Inst | Analogos de quinazolinona y usos de los analogos de quinazolinona para tratar o prevenir ciertas infecciones virales. |
US20130164260A1 (en) | 2011-11-16 | 2013-06-27 | Gilead Sciences, Inc. | Antiviral compounds |
ES2626484T3 (es) | 2011-12-20 | 2017-07-25 | Riboscience Llc | Derivados nucleosídicos 4'-azido-3'-fluoro-sustituidos como inhibidores de la replicación del ARN de VHC |
US20150087045A1 (en) * | 2012-01-13 | 2015-03-26 | Gilead Pharmassset Llc | Crystal structure of hcv polymerase complexes and methods of use |
US20130309196A1 (en) * | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
US10034893B2 (en) | 2013-02-01 | 2018-07-31 | Enanta Pharmaceuticals, Inc. | 5, 6-D2 uridine nucleoside/tide derivatives |
US9167288B2 (en) | 2013-03-15 | 2015-10-20 | Universal Electronics Inc. | System and method for optimizing memory usage in a universal controlling device |
MA38678A1 (fr) | 2013-05-16 | 2017-07-31 | Riboscience Llc | Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués |
US20180200280A1 (en) | 2013-05-16 | 2018-07-19 | Riboscience Llc | 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication |
SG11201509424VA (en) * | 2013-05-16 | 2015-12-30 | Riboscience Llc | 4'-fluor0-2'-methyl substituted nucleoside derivatives |
JP2016538317A (ja) * | 2013-08-26 | 2016-12-08 | エナンタ ファーマシューティカルズ インコーポレイテッド | C型肝炎を防止または治療するための新規シクロスポリン類似体 |
ES2900570T3 (es) | 2013-08-27 | 2022-03-17 | Gilead Pharmasset Llc | Formulación de combinación de dos compuestos antivirales |
TWI721947B (zh) | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
US9675632B2 (en) | 2014-08-26 | 2017-06-13 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
US9669095B2 (en) | 2014-11-03 | 2017-06-06 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues for preventing or treating hepatitis C infection |
WO2016073756A1 (en) | 2014-11-06 | 2016-05-12 | Enanta Pharmaceuticals, Inc. | Deuterated nucleoside/tide derivatives |
US9732110B2 (en) | 2014-12-05 | 2017-08-15 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
CN104530189B (zh) * | 2014-12-16 | 2017-11-14 | 郑州大学第一附属医院 | 丙型肝炎病毒ns5b rna聚合酶抑制多肽序列及其用途 |
KR20200056420A (ko) | 2017-09-21 | 2020-05-22 | 리보사이언스 엘엘씨 | Hcv rna 복제의 억제제로서 4'-플루오로-2'-메틸 치환된 뉴클레오시드 유도체 |
WO2023172635A1 (en) * | 2022-03-08 | 2023-09-14 | Emory University | Predictive model for variants associated with drug resistance and theranostic applications thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5528559A (en) * | 1995-06-23 | 1996-06-18 | Motorola, Inc. | Multiple display timepiece |
EP1076692A2 (en) * | 1998-05-04 | 2001-02-21 | Vertex Pharmaceuticals Incorporated | Crystallizable jnk complexes |
US6434489B1 (en) * | 2000-04-03 | 2002-08-13 | Schering Corporation | Compositions of hepatitis C virus NS5B polymerase and methods for crystallizing same |
US6448281B1 (en) * | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
EP1256628A3 (en) * | 2001-05-10 | 2003-03-19 | Agouron Pharmaceuticals, Inc. | Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof |
CA2448737C (en) * | 2001-07-20 | 2010-06-01 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
EP1436323A4 (en) * | 2001-09-06 | 2005-03-16 | Biogen Idec Inc | CRYSTALLINE STRUCTURE OF BAFF AND USE FOR THE DESIGN OF MEDICAMENTS |
US7223785B2 (en) * | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
-
2004
- 2004-05-05 WO PCT/CA2004/000676 patent/WO2004099241A1/en active Application Filing
- 2004-05-05 CN CNB2004800194730A patent/CN100457776C/zh not_active Expired - Fee Related
- 2004-05-05 EP EP04731118.8A patent/EP1625154B1/en not_active Expired - Lifetime
- 2004-05-05 JP JP2006500449A patent/JP4584909B2/ja not_active Expired - Fee Related
- 2004-05-05 ES ES04731118.8T patent/ES2456702T3/es not_active Expired - Lifetime
- 2004-05-05 MX MXPA05012101A patent/MXPA05012101A/es active IP Right Grant
- 2004-05-05 DK DK04731118.8T patent/DK1625154T3/da active
- 2004-05-05 KR KR1020057021262A patent/KR101164070B1/ko not_active IP Right Cessation
- 2004-05-05 CA CA2522574A patent/CA2522574C/en not_active Expired - Fee Related
- 2004-05-05 AU AU2004235848A patent/AU2004235848B2/en not_active Ceased
- 2004-05-07 US US10/842,046 patent/US7386398B2/en active Active
-
2005
- 2005-11-07 IL IL171800A patent/IL171800A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN1820022A (zh) | 2006-08-16 |
KR101164070B1 (ko) | 2012-07-12 |
AU2004235848A1 (en) | 2004-11-18 |
CA2522574C (en) | 2015-07-07 |
ES2456702T3 (es) | 2014-04-23 |
US20050003348A1 (en) | 2005-01-06 |
CA2522574A1 (en) | 2004-11-18 |
KR20060011861A (ko) | 2006-02-03 |
DK1625154T3 (da) | 2014-02-24 |
AU2004235848B2 (en) | 2011-08-04 |
EP1625154A1 (en) | 2006-02-15 |
WO2004099241A1 (en) | 2004-11-18 |
US7386398B2 (en) | 2008-06-10 |
EP1625154B1 (en) | 2014-01-08 |
CN100457776C (zh) | 2009-02-04 |
IL171800A (en) | 2013-06-27 |
JP2007534292A (ja) | 2007-11-29 |
JP4584909B2 (ja) | 2010-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA05012101A (es) | Bolsillo de union al inhibidor de polimerasa ns5b del virus de la hepatitis c. | |
WO2004014852A3 (en) | Iminothiazolidinones as inhibitors of hcv replication | |
TW200518746A (en) | Novel inhibitors of hepatitis C virus NS3/NS4A serine protease | |
EP1771454A4 (en) | PEPTIDE ANALOGUE AS HEPATITIS C HEMMER | |
TW200615275A (en) | Hepatitis C inhibitor dipeptide analogs | |
UA86962C2 (en) | Viral polymerase inhibitors | |
WO2001074768A3 (en) | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease | |
ATE474827T1 (de) | Hcv-replikationshemmer | |
WO2006086381A3 (en) | Hepatitis c virus inhibitors | |
ME00382B (me) | Inhibitorna jedinjenja za hepatitis c | |
DE60319820D1 (de) | Pyrazoloä1,5-aüpyrimidin-verbindungen als antivirale agentien | |
ATE542826T1 (de) | Inhibitoren des hepatitis-c-virus | |
TW200728317A (en) | Macrocylic inhibitors of hepatitis C virus | |
TW200745120A (en) | Indolobenzazepine HCV NS5B inhibitors | |
WO2004032827A3 (en) | Hepatitis c virus inhibitors | |
ATE481106T1 (de) | Heterocyclische sulfonamid-hepatitis-c-virus- hemmer | |
RS67004A (en) | Macrocyclic peptides active against the hepatitis c virus | |
MX2007000007A (es) | Inhibidores de polimerasa viral. | |
MXPA05008106A (es) | Inhibidores del virus de la hepatitis c, composiciones y tratamientos que los emplean. | |
ATE486889T1 (de) | Peptidanaloga mit inhibitorischer wirkung auf hepatitis c | |
WO2007027248A3 (en) | 3', 5' - cyclic nucleoside analogues for treatment of hcv | |
EA200900676A1 (ru) | Ингибиторы вируса гепатита с | |
WO2005000308A3 (en) | Methods of identifying hcv ns5b polymerase inhibitors and use against hepatitis c | |
ATE412005T1 (de) | Zyklosporinanalog | |
WO2003051910A3 (en) | Inhibitors of hepatitis c virus protease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |